Skip to content

Insider · CIK 0001493056

Preston Klassen

presidentofficerdirector

Files at RGLS (Regulus Therapeutics Inc.). First filing Jan 15, 2025, latest Jun 4, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 1
$96k bought, $40k sold

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
36Weak
RGLSbuy
Regulus Therapeutics Inc.
$96k
12,000 shares
+33%-
31Weak
RGLSsell 410b5-1
Regulus Therapeutics Inc.
$40k
31,445 shares
-47%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jun 25, 2025RGLS
Regulus Therapeutics Inc.
DDisposition to issuer
Common Stock
-115,555--0Jun 27, 2025
Jun 25, 2025RGLS
Regulus Therapeutics Inc.
DDisposition to issuer
Stock Optionderivative
-350,000--0Jun 27, 2025
Jun 25, 2025RGLS
Regulus Therapeutics Inc.
DDisposition to issuer
Stock Optionderivative
-225,000--0Jun 27, 2025
Jun 25, 2025RGLS
Regulus Therapeutics Inc.
DDisposition to issuer
Stock Optionderivative
-120,000--0Jun 27, 2025
Jun 25, 2025RGLS
Regulus Therapeutics Inc.
DDisposition to issuer
Stock Optionderivative
-528,000--0Jun 27, 2025
Jun 25, 2025RGLS
Regulus Therapeutics Inc.
DDisposition to issuer
Stock Optionderivative
-675,000--0Jun 27, 2025
Jun 3, 2025RGLS
Regulus Therapeutics Inc.
POpen-market purchase
Common Stock
+12,000$7.99$96k48,055Jun 4, 2025
Jan 30, 2025RGLS
Regulus Therapeutics Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+675,000$0.00$0675,000Jan 31, 2025
Jan 13, 2025RGLS
Regulus Therapeutics Inc.
SOpen-market sale
Common Stock10b5-1
-31,445$1.26$40k36,055Jan 15, 2025
Jan 9, 2025RGLS
Regulus Therapeutics Inc.
AGrant or award
Common Stock
+37,500$1.36$51k37,500Jan 10, 2025
Jan 9, 2025RGLS
Regulus Therapeutics Inc.
AGrant or award
Common Stock
+30,000$1.30$39k67,500Jan 10, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Preston Klassen: insider trades and track record | InsiderTell